secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001193125-25-115489
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q1 2025 net loss $46.9M; pipeline progress in obesity, AATD, DMD, HD
--------------------------------------------------------------------------------

- Net loss of $46.9M vs $31.6M prior year; revenue $9.2M (down from $12.5M). Cash $243.1M, runway into 2027.
- Obesity: dosing complete in first two INLIGHT cohorts for WVE-007; clinical data expected 2H 2025.
- AATD: RestorAATion-2 dosing at 200 mg Q2W and 400 mg single dose; data on multiple cohorts due 3Q and fall 2025.
- DMD: Positive 48-week FORWARD-53 data with 3.8 sec improvement in TTR vs natural history; NDA submission planned 2026.
- HD: IND submission expected 2H 2025 for potentially registrational Phase 2/3 study of WVE-003.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525115489/0001193125-25-115489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525115489/d892783d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-115489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer